Jan Novak1, Dana Rizk1, Kazuo Takahashi2, XianWen Zhang3, Qi Bian4, Hirouki Ueda1, Yoshimi Ueda1, Colin Reily1, Ling-Yun Lai5, Chuanming Hao6, Lea Novak1, Zhi-Qiang Huang1, Matthew B Renfrow1, Hitoshi Suzuki7, Bruce A Julian1. 1. University of Alabama at Birmingham, Birmingham, AL, USA. 2. University of Alabama at Birmingham, Birmingham, AL, USA ; School of Medicine, Fujita Health University, Toyoake, Japan. 3. University of Alabama at Birmingham, Birmingham, AL, USA ; Longhua Hospital, Shanghai University of TCM, Shanghai, China. 4. University of Alabama at Birmingham, Birmingham, AL, USA ; Changhai Hospital, Second Military Medical University, Shanghai, China. 5. University of Alabama at Birmingham, Birmingham, AL, USA ; Fudan University Huashan Hospital, Shanghai, China. 6. Fudan University Huashan Hospital, Shanghai, China. 7. University of Alabama at Birmingham, Birmingham, AL, USA ; Juntendo University Faculty of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: IgA nephropathy, a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (autoantigen) and anti-glycan autoantibodies deposit in glomeruli and induce renal injury. Multiple genetic loci associated with disease risk have been identified. The prevalence of risk alleles varies geographically, highest in eastern Asia and northern Europe, fewer in other parts of Europe and North America, and the least in Africa. IgA nephropathy is diagnosed from pathological assessment of a renal biopsy specimen. Currently, therapy is not disease-targeted but rather is focused on maintaining control of blood pressure and proteinuria, ideally with suppression of angiotensin II. Possible additional approaches differ between countries. Disease-specific therapy as well as new tools for diagnosis, prognosis, and assessment of responses to therapy are needed. SUMMARY: Glycosylation pathways associated with aberrant O-glycosylation of IgA1 and, thus, production of autoantigen, have been identified. Furthermore, unique characteristics of the autoantibodies in IgA nephropathy have been uncovered. Many of these biochemical features are shared by patients with IgA nephropathy and Henoch-Schönlein purpura nephritis, suggesting that the two diseases may represent opposite ends of a spectrum of a disease process. Understanding the molecular mechanisms involved in formation of pathogenic IgA1-containing immune complexes will enable development of disease-specific therapies as well as diagnostic and prognostic biomarkers. KEY MESSAGES: IgA nephropathy is an autoimmune disease caused by glomerular deposition of nephritogenic circulating immune complexes consisting of galactose-deficient IgA1 (autoantigen) bound by anti-glycan autoantibodies. A better understanding of the multi-step process of pathogenesis of IgA nephropathy and the genetic and environmental contributing factors will lead to development of biomarkers to identify patients with progressive disease who would benefit from a future disease-specific therapy.
BACKGROUND: IgA nephropathy, a frequent cause of end-stage renal disease, is an autoimmune disease wherein immune complexes consisting of IgA1 with galactose-deficient O-glycans (autoantigen) and anti-glycan autoantibodies deposit in glomeruli and induce renal injury. Multiple genetic loci associated with disease risk have been identified. The prevalence of risk alleles varies geographically, highest in eastern Asia and northern Europe, fewer in other parts of Europe and North America, and the least in Africa. IgA nephropathy is diagnosed from pathological assessment of a renal biopsy specimen. Currently, therapy is not disease-targeted but rather is focused on maintaining control of blood pressure and proteinuria, ideally with suppression of angiotensin II. Possible additional approaches differ between countries. Disease-specific therapy as well as new tools for diagnosis, prognosis, and assessment of responses to therapy are needed. SUMMARY: Glycosylation pathways associated with aberrant O-glycosylation of IgA1 and, thus, production of autoantigen, have been identified. Furthermore, unique characteristics of the autoantibodies in IgA nephropathy have been uncovered. Many of these biochemical features are shared by patients with IgA nephropathy and Henoch-Schönlein purpura nephritis, suggesting that the two diseases may represent opposite ends of a spectrum of a disease process. Understanding the molecular mechanisms involved in formation of pathogenic IgA1-containing immune complexes will enable development of disease-specific therapies as well as diagnostic and prognostic biomarkers. KEY MESSAGES: IgA nephropathy is an autoimmune disease caused by glomerular deposition of nephritogenic circulating immune complexes consisting of galactose-deficient IgA1 (autoantigen) bound by anti-glycan autoantibodies. A better understanding of the multi-step process of pathogenesis of IgA nephropathy and the genetic and environmental contributing factors will lead to development of biomarkers to identify patients with progressive disease who would benefit from a future disease-specific therapy.
Entities:
Keywords:
Autoantibodies; IgA nephropathy; O-glycans; galactose deficiency; immune complexes
Authors: Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian Journal: J Am Soc Nephrol Date: 2008-02-13 Impact factor: 10.121
Authors: Alice C Smith; Jacob F de Wolff; Karen Molyneux; John Feehally; Jonathan Barratt Journal: J Am Soc Nephrol Date: 2006-03-01 Impact factor: 10.121
Authors: Richard A Lafayette; Pietro A Canetta; Brad H Rovin; Gerald B Appel; Jan Novak; Karl A Nath; Sanjeev Sethi; James A Tumlin; Kshama Mehta; Marie Hogan; Stephen Erickson; Bruce A Julian; Nelson Leung; Felicity T Enders; Rhubell Brown; Barbora Knoppova; Stacy Hall; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2016-11-07 Impact factor: 10.121
Authors: Tyler J Stewart; Kazuo Takahashi; Robert H Whitaker; Milan Raska; William J Placzek; Jan Novak; Matthew B Renfrow Journal: Glycobiology Date: 2019-07-01 Impact factor: 4.313
Authors: Hannah J Lomax-Browne; Claire Robertson; Aristotelis Antonopoulos; Anthony J C Leathem; Stuart M Haslam; Anne Dell; Miriam V Dwek Journal: Interface Focus Date: 2019-02-15 Impact factor: 3.906
Authors: Koshi Yamada; Zhi Qiang Huang; Milan Raska; Colin Reily; Joshua C Anderson; Hitoshi Suzuki; Krzysztof Kiryluk; Ali G Gharavi; Bruce A Julian; Christopher D Willey; Jan Novak Journal: Kidney Dis (Basel) Date: 2020-04-16
Authors: Hannah J Lomax-Browne; Alessia Visconti; Charles D Pusey; H Terence Cook; Tim D Spector; Matthew C Pickering; Mario Falchi Journal: J Am Soc Nephrol Date: 2016-06-16 Impact factor: 10.121